China Medical System Holdings: Desidustat Tablets Approved for Renal Anaemia in China

Key Highlights

• Regulatory Milestone: On 13 March 2026, China Medical System Holdings Limited (CMS) announced that its new drug, Desidustat Tablets, has been approved for marketing in China by the National Medical Products Administration (NMPA).
• Therapeutic Innovation: Desidustat Tablets is a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) designed for the treatment of anaemia in non-dialysis adult patients with Chronic Kidney Disease (CKD).
• Strong Clinical Results: The China Phase III clinical trial demonstrated that Desidustat is significantly more effective than placebo in increasing haemoglobin (Hb) levels and can maintain these levels within the target range over the long term with acceptable safety. The drug also improves iron metabolism by reducing hepcidin levels.
• Market Opportunity: CKD affects over 120 million people in China, with anaemia being a common and serious complication. There is a significant unmet need, especially among non-dialysis CKD patients where only 8.2% achieve target Hb levels under current treatments.
• Strategic Portfolio Expansion: Desidustat Tablets will bolster CMS’s nephrology portfolio, complementing its existing marketed drug, Velphoro (for CKD hyperphosphatemia), and is expected to leverage the company’s established expert resources and networks.
• Exclusive License: CMS holds an exclusive license for Desidustat in China, obtained from Zydus Lifesciences Limited (formerly Cadila Healthcare Limited) under an agreement effective from 20 January 2020.
• International Approval: Desidustat Tablets has also been approved for marketing in India.

Implications for Shareholders and Potential Price Sensitivity

• Significant Market Potential: The huge CKD patient population in China and the low rate of effective anaemia treatment in non-dialysis patients represent a substantial commercial opportunity. The oral administration of Desidustat is expected to improve patient compliance and address significant unmet needs, positioning CMS for strong market uptake.
• Financial Impact: The approval of Desidustat Tablets is expected to have a positive effect on CMS’s financial results. This new product launch strengthens the company’s competitive position in the nephrology field and is likely to drive revenue growth.
• Synergistic Growth: The integration of Desidustat with CMS’s existing nephrology products, particularly Velphoro, allows for cross-promotion and efficient channel utilization, accelerating the clinical adoption of both therapies.
• Competitive Edge: The addition of a first-in-class oral HIF-PHI therapy to CMS’s pipeline may provide the company with a unique competitive advantage in the rapidly evolving nephrology market in China.
• Shareholder Advisory: This announcement is made on a voluntary basis. Shareholders and investors are advised to exercise caution when dealing in the shares and other securities of the Company, as the product’s market performance and regulatory impacts are still subject to further development.

Further Details

Chronic Kidney Disease (CKD) is a progressive condition leading to kidney failure and associated complications such as anaemia. Erythropoietin (EPO) production declines as kidney function worsens, resulting in reduced red blood cell production. Desidustat Tablets, as a HIF-PHI, work by stimulating endogenous EPO production, improving iron availability, and lowering hepcidin, thereby enhancing erythropoiesis.

The China Phase III clinical trial for Desidustat met its primary endpoint, demonstrating a significant increase in haemoglobin levels compared to placebo during Weeks 7-9. The long-term extension study confirmed maintenance of target Hb levels with a favourable safety profile. Additionally, the drug was shown to address iron metabolism disorders, a critical aspect in the management of CKD anaemia.

Despite improvements in haemodialysis CKD patients, the target haemoglobin rate in non-dialysis patients remains very low, underscoring a large underserved market. Oral administration of Desidustat is a key advantage, expected to support better adherence and outcomes.

CMS plans to rapidly promote the clinical application of Desidustat Tablets through its established network of nephrology experts and channel partners, aiming to provide differentiated treatment options for Chinese patients and further strengthen its market leadership in nephrology.

Corporate Governance

As of the announcement date, the board of directors comprises Mr. Lam Kong (Chairman) and Ms. Chen Yanling as executive directors, and Mr. Leung Chong Shun, Ms. Luo Laura Ying, and Mr. Fung Ching Simon as independent non-executive directors.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Shareholders and investors are encouraged to conduct their own due diligence and consult professional advisors before making investment decisions. The impact of Desidustat Tablets on the company’s financial performance and share price may be influenced by further regulatory, commercial, and clinical developments.

View CMS Historical chart here